SavedAdd your journal

Journals / İnfeksiyon Dergisi / 2005 / Cilt: 19 - Sayı: 2

Efficacy of the combination of zidovudine, lamivudine and nevirapine in the treatment of human immunodeficiency virus infection

İnsan immün yetmezlik virüsü infeksiyonu sağaltımında zidovudin, lamivudin ve nevirapin kombinasyonunun etkinliği

Fatih DEMİRKAN
Altınay BİLGİÇ
Nejat Ali COŞKUN
Işın MÜFTÜOĞLU
Afet ERBAY
Nesrin TÜRKER
Sibel EL
Serap URAL
İlknur VARDAR
Figen KAPTAN
Pages
151–155
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

By four weeks of treatment plasma HIV-1 RNA level decreased significantly (-0.5 log 10) in all of the cases (mean: 2,510 copies/mL) and in two cases decreased to undetectable levels (

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, virological and immunological efficacy of the combination of zidovudine, lamivudine and nevirapine in six cases with human immunodeficiency virus (HIV) infection is evaluated.
📊
Key Findings & Data:At admission mean CD4+ T lymphocyte count and plasma HIV-1 RNA level were 336 cells/mL and 62,000 copies/mL respectively.
💡
Conclusion & Impact:By four weeks of treatment plasma HIV-1 RNA level decreased significantly (-0.5 log 10) in all of the cases (mean: 2,510 copies/mL) and in two cases decreased to undetectable levels (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study, virological and immunological efficacy of the combination of zidovudine, lamivudine and nevirapine in six cases with human immunodeficiency virus (HIV) infection is evaluated. At admission mean CD4+ T lymphocyte count and plasma HIV-1 RNA level were 336 cells/mL and 62,000 copies/mL respectively. By four weeks of treatment plasma HIV-1 RNA level decreased significantly (-0.5 log 10) in all of the cases (mean: 2,510 copies/mL) and in two cases decreased to undetectable levels (

Özet

Bu çalışmada, insan immün yetmezlik virüsü (HIV) infeksiyonu tanısı ile izlenen altı olguda zidovudin, lamivudin ve nevirapin kombinasyonunun sağaltımdaki virolojik ve immünolojik etkinliği değerlendirilmiştir, ilk başvuruda CD4+ T lenfosit sayısı ve plazma HIV-1 RNA düzeyi sırasıyla ortalama 336 hücre/mm3 ve 62.000 kopya/mL olarak saptanmıştır. Sağaltımın dördüncü haftasında hastaların tümünde plazma HIV-1 RNA düzeyi anlamlı olarak (-0,5 log 10) azalmış (ortalama: 2.510 kopya/mL) ve iki olguda ölçülemeyecek düzeye (

🔖

Cite This Article

DEMİRKAN, F., BİLGİÇ, A., COŞKUN, N. A., MÜFTÜOĞLU, I., ERBAY, A., TÜRKER, N., EL, S., URAL, S., VARDAR, İ., KAPTAN, F. (2022). Efficacy of the combination of zidovudine, lamivudine and nevirapine in the treatment of human immunodeficiency virus infection. İnfeksiyon Dergisi, Cilt: 19 - Sayı: 2, 151–155. https://ajindex.com/articles/546489

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Hanna GJ, Hirsch MS. Antiretroviral therapy of human immunodeficiency virus infection. In: Mandell GL, Bennet JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000; 1479-500
  2. Carpenter CJC, Cooper DA, FischI MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society. USA Panel. JAMA 2000; 283: 381-90
  3. Murphy RL, Montaner J. Nevirapine: a review of development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996;5:1183-99
  4. Mascolini M. Crossing the waters to the post-HAART era. Journal of International Association of Physicians in AIDS Care 1999; 5: 12-51
  5. Deeks SG, Hellmann NS, Grant RWI, et al. Novel four drug salvage treatment regimens after failure of a Human Immunodeficiency Virus Type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. JID 1999; 179:1375-81
  6. Mascolini M. Starting, stoping, picking and swiching antiretrovirals or, the ring in the river. Association of Physicians in AIDS Care 2001; 7: 54-65
  7. Floridia M, Bucciardini R, Ricciardulli D, et al. Randomized, double-blind trial on the use of a tripple combination including nevi rapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. JAID Syndr and Human Retrovir 1999;20: 11-9
  8. Pollard RB, Cahn P, Cassuto J, et al. Durable HIV suppression with nevirapin (NVP), zidovudin (ZDV) and lamivudine (3TC) in treatment-naive patients with AIDS and high viral load [Abstract]. In: 7th European Conference on Clinical Aspects and Treatment of HIV Infection (1999, Lisbon). 1999: Abstract no. 1218
  9. Montaner JSG, Reiss P, Cooper D, et al. For the INCAS Study Group. A randomized, double-blind trial comparing combinations of nevirapin, didanosine and zidovudine for HIV-infected patients, The INCAS Trial. JAMA 1998; 279: 930-7
  10. Murphy R, Katlama C, Johnson V, et al. The Atlantic Study: A randomized, open-label trial comparing two protease inhibitor (Pl)-sparing antiretroviral strategies versus a standard Pl-containing regimen, 48 week data [Abstract]. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (1999, San Francisco, California). 1999: Abstract no. LB 22.